JAMA Studies Provide More Ammunition For Trial Disclosure Reformers
This article was originally published in The Pink Sheet Daily
Executive Summary
JAMA studies focus on the high number of terminated and unreported trials, plus discrepancies in publicly reported trial results. Publication comes as the Institute of Medicine consults stakeholders about trial data sharing and ahead of new reporting laws in Europe.
You may also be interested in...
FDA Post-Marketing Study Compliance Efforts To Get HHS OIG Review
The HHS watchdog will also continue its look at generic drug facility inspections and supply chain oversight, according to its fiscal year 2015 work plan.
J&J’s Clinical Data Disclosure Strategy Focuses On Collaboration With Yale University Group
In what appears to be the most expansive policy to date on release of clinical trial data, J&J will use an existing outside group and will share full clinical study reports and patient-level data regardless of when the studies were conducted.
IOM Plans Study To Facilitate Clinical Trial Data Sharing
The Institute of Medicine issued a draft framework for a study on expanding clinical trial data sharing and is seeking input from outside parties. The draft discusses how competing firms, disease advocacy groups and the media might responsibly use data shared by clinical trial sponsors.